Liminatus Pharma, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -98.5% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| ZCMDZhongchao Inc. | $0.92 | — | 0.1x | — | -24.88% | $5.69M |
| WOKWORK Medical Technology Group LTD | $2.33 | — | 0.0x | — | -19.23% | $5.63M |
| NIKINiki BioSolutions, Inc. | $6.90 | — | 0.3x | — | -17.05% | $5.62M |
| KAPAKairos Pharma, LTD. | $0.24 |
Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.
Company description provided by Yahoo Finance.
| — |
| 1.2x |
| — |
| -113.96% |
| $5.62M |
| YCBDcbdMD, Inc. | $0.50 | 2.2x | 0.6x | — | -40.33% | $5.6M |
| NCNANuCana plc | $1.33 | 0.0x | 0.2x | — | -70.26% | $5.54M |